In person ZoBio will participate in Discovery on Target, the industry’s premier event focused on novel drug targets and cutting-edge technologies for drug discovery professionals. The conference always showcase the latest advancements in both current and emerging “hot” targets, as well as innovative target validation strategies for developing novel therapeutic agents, from biologics to small…
FBDD Suitability Screening
Are you unsure whether Fragment Based Drug Discovery is a valid approach for your target?
Fragment Based Drug Discovery is now a well-established method to develop small molecule therapeutics for challenging drug targets. Orthosteric inhibitors, allosteric inhibitors (Asciminib) and Molecular Glues (ImIDs) are just some of the mechanisms of action…
A Fast Route to Success in Molecular Glue Discovery
Are you developing or thinking of developing small molecule therapeutics against a really challenging target? If so, does one of these scenarios describe your situation?
– You are trying to determine which small molecule approach is best for your target (orthosteric/allosteric inhibitor, degrader…
10th RSC-BMCS Fragment-based Drug Discovery Meeting
In person ZoBio is pleased to attend the RSC-BMCS Fragment-Based Drug Discovery meeting in Cambridge this September. ZoBio will be represented by Johan Veerman | LinkedIn, Head of Chemistry, who will also present a poster entitled: Site-selective screening: Design, synthesis and application of stable S-adenosylmethionine-based probes for fragment screening against METTL3/14 We look forward to…